Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan FP, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Jeger RV, et al. Among authors: gilgen n. Lancet. 2018 Sep 8;392(10150):849-856. doi: 10.1016/S0140-6736(18)31719-7. Epub 2018 Aug 28. Lancet. 2018. PMID: 30170854 Free article. Clinical Trial.
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
Jeger R, Pfisterer M, Alber H, Eberli F, Galatius S, Naber C, Pedrazzini G, Rickli H, Jensen JS, Vuilliomenet A, Gilgen N, Kaiser C. Jeger R, et al. Among authors: gilgen n. Am Heart J. 2012 Feb;163(2):136-41.e1. doi: 10.1016/j.ahj.2011.08.023. Am Heart J. 2012. PMID: 22305828 Clinical Trial.
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz DJ, Pedrazzini G, Moccetti T, Rickli H, Weilenmann D, Vuillomenet A, Steiner M, Von Felten S, Vogt DR, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M; BASKET-PROVE II study group. Kaiser C, et al. Among authors: gilgen n. Circulation. 2015 Jan 6;131(1):74-81. doi: 10.1161/CIRCULATIONAHA.114.013520. Epub 2014 Nov 19. Circulation. 2015. PMID: 25411159 Clinical Trial.
Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.
Gilgen N, Farah A, Scheller B, Ohlow MA, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, Zweiker R, Krackhardt F, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan FP, Coslovsky M, Jeger R; BASKET-SMALL 2 Investigators. Gilgen N, et al. Clin Cardiol. 2018 May;41(5):569-575. doi: 10.1002/clc.22942. Epub 2018 May 10. Clin Cardiol. 2018. PMID: 29527709 Free PMC article. Clinical Trial.
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
Jeger RV, Pfisterer M, Vogt DR, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz DJ, Pedrazzini G, Vuilliomenet A, Weilenmann D, Rickli H, Hansen KW, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Kaiser C. Jeger RV, et al. Among authors: gilgen n. PLoS One. 2019 Jan 15;14(1):e0210821. doi: 10.1371/journal.pone.0210821. eCollection 2019. PLoS One. 2019. PMID: 30645635 Free PMC article.
Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial.
Fahrni G, Scheller B, Coslovsky M, Gilgen N, Farah A, Ohlow MA, Mangner N, Weilenmann D, Wöhrle J, Cuculi F, Leibundgut G, Möbius-Winkler S, Zweiker R, Twerenbold R, Kaiser C, Jeger R; BASKET-SMALL 2 Investigators. Fahrni G, et al. Among authors: gilgen n. Clin Res Cardiol. 2020 Sep;109(9):1114-1124. doi: 10.1007/s00392-020-01603-2. Epub 2020 Jan 29. Clin Res Cardiol. 2020. PMID: 31993736 Clinical Trial.
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Jeger RV, et al. Among authors: gilgen n. Lancet. 2020 Nov 7;396(10261):1504-1510. doi: 10.1016/S0140-6736(20)32173-5. Epub 2020 Oct 19. Lancet. 2020. PMID: 33091360 Clinical Trial.
Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial.
Wöhrle J, Scheller B, Seeger J, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Stachel G, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Jeger RV; BASKET-SMALL 2 Investigators. Wöhrle J, et al. Among authors: gilgen n. JACC Cardiovasc Interv. 2021 Aug 23;14(16):1789-1798. doi: 10.1016/j.jcin.2021.06.025. JACC Cardiovasc Interv. 2021. PMID: 34412797 Free article. Clinical Trial.
23 results